Bluejay Therapeutics Announces Data Presentations in Chronic Hepatitis D (CHD) and Chronic Hepatitis B (CHB) at Upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025

REDWOOD CITY, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) — Bluejay Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing potentially life-changing therapeutics for serious viral and liver diseases, today announced upcoming presentations highlighting new data from its chronic hepatitis D (CHD) and chronic hepatitis B (CHB) programs at the American Association for the Study of […] The post Bluejay Therapeutics Announces Data Presentations in Chronic Hepatitis D (CHD) and Chronic Hepatitis B (CHB) at Upcoming American Association for the Study of Liver Diseases (AASLD